AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oramed Pharmaceuticals Inc.

Regulatory Filings Jan 4, 2023

6965_rns_2023-01-04_317fe848-d31a-4d36-a149-a95758406350.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

Instruction 1(b).

Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
Rabinowitz
Michael
2. Issuer Name and Ticker or Trading Symbol
Oramed Pharmaceuticals Inc. [ORMP]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_ Director
_ 10% Owner
(Last)
(First)
(Middle)
1185 Avenue of the Americas
3. Date of Earliest Transaction (Month/Day/Year)
01/03/2023
Officer (give title below)____ Other (specify below)
X
Chief Commercial Officer
(Street)
New York
NY
10036
(City)
(State)
(Zip)
4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
X
Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security
(Instr. 3)
2. Transaction
2A. Deemed
Date
Execution Date, if
(Month/Day/Year)
any
3. Transaction
Code
(Instr. 8)
4. Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities
Beneficially Owned Following
Reported Transaction(s)
6.
Ownership
Form:
7. Nature of
Indirect
Beneficial
(Month/Day/Year) Code V Amount (A) or
(D)
Price (Instr. 3 and 4) Direct (D)
or Indirect
(I)
(Instr. 4)
Ownership
(Instr. 4)
Common Stock (1)
01/03/2023
S 1,425 D \$13.0132 138,043 D
Common Stock (1)
01/03/2023
S 11,900 D \$12.4917
(2)
126,143 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction 3A. Deemed 4. 8. Price of 9. Number of 10. 11. Nature
Derivative Conversion Date Execution Date, if Transaction 5. Number
of
6. Date Exercisable and
Expiration Date
7. Title and
Amount of
Derivative Derivative Ownership of Indirect
Security or Exercise (Month/Day/Year) any Code Derivative (Month/Day/Year) Underlying Security Securities Form of Beneficial
(Instr. 3) Price of (Month/Day/Year) (Instr. 8) Securities Securities (Instr. 5) Beneficially Derivative Ownership
Derivative Acquired (Instr. 3 and 4) Owned Security: (Instr. 4)
Security (A) or Following Direct (D)
Disposed of Reported or Indirect
(D) Transaction(s) (I)
(Instr. 3, 4, (Instr. 4) (Instr. 4)
and 5)
Amount
or
Date Expiration Number
Code V (A) (D) Exercisable Date Title of Shares

Explanation of Responses:

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.01 to \$13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

/s/ Michael Rabinowitz 01/04/2023

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Talk to a Data Expert

Have a question? We'll get back to you promptly.